Quoin Pharmaceuticals will release Q2 financial results and operational updates on August 7, 2025, highlighting key achievements.
Quiver AI Summary
Quoin Pharmaceuticals Ltd. announced that it will release its financial results for the second quarter ending June 30, 2025, on August 7, 2025, before the market opens. The announcement will include an operational update highlighting key achievements and financial highlights from the quarter. Quoin Pharmaceuticals is a late clinical-stage company specializing in developing treatments for rare and orphan diseases, with a pipeline that includes four products aimed at conditions such as Netherton Syndrome and Epidermolysis Bullosa. The company's mission is to meet the unmet medical needs of patients and their communities.
Potential Positives
- Quoin Pharmaceuticals will provide an operational update with key achievements and financial highlights, indicating transparency and engagement with stakeholders.
- The company is focused on developing innovative therapeutic products for rare and orphan diseases, addressing significant unmet medical needs in a specialized market.
- Quoin's product pipeline includes treatments for multiple rare conditions, showcasing the potential for growth and impact in a niche therapeutic area.
Potential Negatives
- The press release lacks any specific financial results or projections, which may raise concerns among investors about the company's transparency and financial health.
- There is no information provided on sales performance, which could indicate potential struggles in commercialization or market acceptance of their products.
FAQ
When will Quoin Pharmaceuticals release its Q2 2025 financial results?
Quoin Pharmaceuticals plans to release its financial results for Q2 2025 on August 7, 2025, before the market opens.
What will be included in the financial results announcement?
The announcement will include operational updates, key achievements, and financial highlights from the second quarter.
What is the focus of Quoin Pharmaceuticals?
Quoin Pharmaceuticals focuses on developing therapeutic products for rare and orphan diseases, addressing unmet medical needs.
How many products are in Quoin’s pipeline?
Quoin's innovative pipeline comprises four products in development targeting various rare and orphan indications.
Where can I find more information about Quoin Pharmaceuticals?
For more information, visit Quoin Pharmaceuticals' official website at www.quoinpharma.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$QNRX Hedge Fund Activity
We have seen 6 institutional investors add shares of $QNRX stock to their portfolio, and 11 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC removed 530,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $118,667
- ALTIUM CAPITAL MANAGEMENT LLC removed 282,249 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $63,195
- RENAISSANCE TECHNOLOGIES LLC removed 133,122 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $29,806
- BOOTHBAY FUND MANAGEMENT, LLC removed 80,712 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $18,071
- XTX TOPCO LTD removed 31,047 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $6,951
- HRT FINANCIAL LP removed 27,714 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $6,205
- RAYMOND JAMES FINANCIAL INC removed 24,401 shares (-97.1%) from their portfolio in Q1 2025, for an estimated $5,463
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
ASHBURN, Va., July 31, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to release its financial results for the second quarter ended June 30, 2025, before the market opens on Thursday, August 7, 2025.
The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, go to:
www.quoinpharma.com
.
For further information, contact:
Quoin Pharmaceuticals Ltd.
Michael Myers, Ph.D., CEO
[email protected]
Investor Relations
PCG Advisory
Jeff Ramson
[email protected]
(646) 863-6341
